Edition:
United States

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

34.21USD
15 Dec 2017
Change (% chg)

$0.34 (+1.00%)
Prev Close
$33.87
Open
$33.89
Day's High
$34.58
Day's Low
$33.48
Volume
595,630
Avg. Vol
148,564
52-wk High
$38.86
52-wk Low
$15.97

Latest Key Developments (Source: Significant Developments)

Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Aimmune Therapeutics Inc :Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018.Aimmune Therapeutics Inc - ‍CEO Stephen Dilly plans to retire by end of 2018​.Aimmune Therapeutics Inc - ‍Aimmune will initiate a search for a successor CEO​.Aimmune Therapeutics Inc - ‍Dilly will continue as Aimmune's CEO until his replacement joins company and will be available through a transition period​.Aimmune Therapeutics Inc qtrly ‍on a per share basis, net loss for quarter was $0.63​.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Aimmune Therapeutics Inc - ‍expects last double-blind, placebo-controlled food challenge in phase 3 palisade trial of ar101 will be conducted in Dec. 2017​.Aimmune Therapeutics Inc - ‍cash, cash equivalents, and investments were $212.0 million at Sept 30, 2017, compared to $282.5 million at december 31, 2016​.Aimmune Therapeutics Inc - ‍top-line data from phase 3 palisade trial of ar101 will be available in q1 of 2018​.  Full Article

Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Aimmune Therapeutics Inc :Aimmune Therapeutics announces second quarter 2017 financial results.Qtrly net loss per common share, basic and diluted $0.65.Aimmune Therapeutics Inc - ‍looking forward to completing our core phase 3 Palisade trial around end of this year; continue to anticipate sharing topline results in Q1 2018​.Aimmune Therapeutics Inc - ‍cash, cash equivalents, and investments totaled $237.3 million at June 30, 2017, compared to $282.5 million at December 31, 2016​.  Full Article

Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy
Monday, 12 Jun 2017 04:01pm EDT 

June 12 (Reuters) - Aimmune Therapeutics Inc ::Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy.Aimmune Therapeutics Inc - final study visits projected around year-end 2017; topline data expected in q1 of 2018.Aimmune Therapeutics Inc - more than 97 percent of patients currently on study are through up-dosing phase.  Full Article

CoreRx says co, Aimmune Therapeutics increased manufacturing operations in Florida
Wednesday, 7 Jun 2017 10:20am EDT 

June 7 (Reuters) - CoreRx: :CoreRx and Aimmune Therapeutics have increased manufacturing operations at CoreRx's ICOT Center campus in Clearwater, Florida.New expansion consists of about 20,000 sq ft of manufacturing, warehouse space at CoreRx's 5733 Myerlake Circle (ML-3) location.  Full Article

Aimmune Therapeutics enrolls first patient in late-stage trial of its peanut allergy drug
Thursday, 11 May 2017 08:00am EDT 

May 11 (Reuters) - Aimmune Therapeutics Inc -:Aimmune Therapeutics enrolls first patient in ramses (arc007), a phase 3 clinical trial of ar101 for the treatment of peanut allergy.Aimmune Therapeutics Inc - trial follows same up-dosing and maintenance protocol as aimmune's ongoing phase 3 palisade trial.  Full Article

Aimmune Therapeutics reports Q1 loss per share $0.52
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Aimmune Therapeutics Inc :Aimmune therapeutics announces first quarter 2017 financial results.Q1 loss per share $0.52.Q1 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Aimmune Therapeutics appoints Eric Bjerkholt as CFO
Thursday, 13 Apr 2017 06:00am EDT 

Aimmune Therapeutics Inc : Aimmune Therapeutics appoints Eric Bjerkholt as Chief Financial Officer . Aimmune Therapeutics Inc - Bjerkholt joins Aimmune from Sunesis Pharmaceuticals, Inc. .Aimmune - Co plans to report pivotal phase 3 data around end of 2017, file a BLA and MAA in 2018, and make first commercial launches in 2019 for AR101.  Full Article

Aimmune Therapeutics Q4 loss per share $0.55
Wednesday, 15 Mar 2017 07:00am EDT 

Aimmune Therapeutics Inc : Aimmune Therapeutics announces fourth quarter and full year 2016 financial results . Sees 2017 capital expenditures approximately $5 million . Qtrly loss per share $0.55 . Sees 2017 research and development expenses $95 million - $105 million .Q4 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.  Full Article

Aimmune Therapeutics says Warren Desouza, notified co intention to leave his position as CFO of company on April 16
Wednesday, 14 Dec 2016 05:34pm EST 

Aimmune Therapeutics Inc :Aimmune Therapeutics Inc- On December 8, Warren Desouza, notified co intention to leave his position of CFO of company on April 16, 2017- SEC filing.  Full Article

Aimmune Therapeutics files for mixed shelf of up to $250.0 mln - sec filing
Friday, 2 Sep 2016 04:53pm EDT 

Aimmune Therapeutics Inc :Files for mixed shelf of up to $250.0 million - sec filing.  Full Article

BRIEF-Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​

* Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018